BUSINESS WIRE)--Nov 15, 2018--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for ... read more
Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer's Disease
Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease
